Ignite Creation Date:
2024-05-05 @ 10:32 PM
Last Modification Date:
2024-10-26 @ 10:19 AM
Study NCT ID:
NCT01121120
Status:
TERMINATED
Last Update Posted:
2020-12-08
First Post:
2010-05-09
Brief Title:
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant PBSC in Hodgkin Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Sponsor:
Tarix Pharmaceuticals
Organization:
Tarix Pharmaceuticals
Study Overview
Official Title:
Phase II Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Hodgkin Lymphoma Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Limited Reinfusion of CD34 Cells
Status:
TERMINATED
Status Verified Date:
2020-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TXA127-PBSC
Brief Summary:
The purpose of this study is to determine the safety and effectiveness of TXA127 in accelerating the time it takes for patients to recover their platelet counts following a Autologous Peripheral Blood Stem Cell transplant
Detailed Description:
This is a randomized double-blind Investigator and Study Subject placebo-controlled study
The conditioning regimen and mobilization agents used will be up to the discretion of the Study Center Investigator
The conditioning regimen and mobilization agents used will be up to the discretion of the Study Center Investigator
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None